Skip to main content
. Author manuscript; available in PMC: 2014 Jun 17.
Published in final edited form as: Cancer. 2010 Oct 19;117(6):1236–1244. doi: 10.1002/cncr.25575

Table 3.

Responses to Idarubicin, Cytarabine, and Tipifarnib by Disease Characteristics

Parameter No. CR (%)
Overall 95 61 (64)
Karyotype
 Diploid 41 30 (73)
 Chromosome 5 or 7 abnormalities 19 11 (58)
 t(8;21)/inversion 16 5 4 (80)
 Other abnormalities 29 16 (55)
 Not done 1 0 (0)
FLT3 status
 Mutated 17 13 (76)
 Wild type 66 44 (67)
 Not done 12 4 (33)
Group
 <50 y 43 31 (72)
 ≥50 y, diploid 18 12 (67)
 ≥50 y, other 34 18 (53)

CR indicates complete response.